CBG, CBN, CBC, and THCV: Which Cannabinoid Claims Come From Human Studies, and Which Do Not

The gap between how confidently minor cannabinoids are described and how thinly they have been studied is the largest credibility problem in this corner of the field. CBG, CBN, CBC, and THCV are sold with specific functional claims. Between them they have been the subject of a handful of controlled human trials, several of them industry sponsored, and one of them has never been given to people on its own in a published study at all.

That is not an argument against them. It is an argument for describing each compound at the level of evidence that actually exists behind it, which for most of them is early and for one of them is zero.

Patients spend real money on these products, and in some cases they substitute them for treatments that have been tested. A CBN sleep product with one modest trial behind it is a reasonable thing to try and a poor thing to rely on in place of evaluating a sleep disorder.

There is also a practical safety point that comes directly from the trial data. Oral THCV produced positive urine drug screens for THC in nearly every participant tested at eight hours, which matters for anyone subject to workplace or legal testing and would surprise most people buying a product marketed as non-intoxicating.

THC has the deepest human evidence base of any cannabinoid, and it is still narrower than most people assume. The 2015 JAMA systematic review by Whiting and colleagues pooled 79 randomized trials and 6,462 participants and found moderate-quality evidence for chronic pain and spasticity, with an average reduction of 0.46 points on a 10-point pain scale and 0.36 points on the Ashworth spasticity scale, plus low-quality evidence for chemotherapy-induced nausea and vomiting, weight gain in HIV infection, sleep disorders, and Tourette syndrome.

CBD has the single strongest result in cannabinoid medicine and also several clean failures. In the 2017 New England Journal of Medicine trial by Devinsky and colleagues, cannabidiol at 20 mg per kilogram per day reduced median monthly convulsive seizures in Dravet syndrome from 12.4 to 5.9, against 14.9 to 14.1 on placebo. In a 2022 trial in Pain by Vela and colleagues, synthetic CBD at 20 to 30 mg daily for 12 weeks in 129 patients with hand osteoarthritis or psoriatic arthritis produced a between-group pain difference of 0.23 mm on a 100 mm scale, which is nothing.

Those two results belong together. The same molecule can be transformative in a specific syndrome at a specific dose and inert in a different condition at a consumer dose. That is the correct model for thinking about every other cannabinoid on this list.

Cannabigerol went from having no published clinical trials to having a small number very recently. The first, reported by Cuttler, Stueber, Cooper, and Russo in Scientific Reports in July 2024, was a double-blind, placebo-controlled, crossover field trial in 34 healthy adults given 20 mg of hemp-derived CBG tincture or placebo one week apart. Relative to placebo, CBG produced a significant overall reduction in anxiety, a reduction in stress after the Trier Social Stress Test protocol, and better verbal memory, with no subjective drug effects and no motor or cognitive impairment detected.

The second, published in the Journal of Pharmacology and Experimental Therapeutics in 2026 by Wolinsky and colleagues from Johns Hopkins, took a different approach: a single ascending dose study in 12 healthy adults given 0, 25, 50, 100, and 200 mg of CBG isolate. No drug-related adverse events occurred and liver function tests stayed within normal limits. Subjective effects were minimal, with scattered findings including lower ratings of jittery and active at 50 mg, lower ratings of calm at 100 mg, and increased appetite at 200 mg. The authors summarized CBG as well tolerated with no robust pharmacodynamic effects.

Those two results are not contradictory so much as unsettled. A 34-person crossover with a stress challenge and a 12-person dose escalation without one are measuring different things. The fair statement is that CBG appears safe across a wide oral dose range and that one trial found an anxiolytic signal worth pursuing.

Cannabinol is marketed almost exclusively for sleep, and unlike most minor cannabinoids it has been tested for that purpose. A 2023 double-blind randomized placebo-controlled trial by Bonn-Miller and colleagues in Experimental and Clinical Psychopharmacology randomized 293 adults who rated their sleep as poor or very poor to placebo, 20 mg CBN, or 20 mg CBN with 10, 20, or 100 mg of CBD, nightly for a week. The primary endpoint, sleep quality, did not reach significance. Secondary endpoints did: CBN significantly reduced the number of nighttime awakenings and overall sleep disturbance, with no effect on sleep onset latency, wake after sleep onset, or daytime fatigue. Adding CBD did not improve on CBN alone.

A 2024 trial in Pharmaceuticals by Kolobaric and colleagues compared three doses of a proprietary CBN formulation at 25, 50, and 100 mg against placebo and against 4 mg melatonin, with roughly 200 participants per arm. All CBN groups and the melatonin group improved sleep quality significantly relative to placebo, with no significant differences between any CBN group and melatonin.

The asterisk is sponsorship. The first trial’s authors were affiliated with Canopy Growth Corporation and Wana Brands; the second was run by Radicle Science on a commercial formulation. Industry-sponsored trials are not invalid, and these are more rigorous than most of what exists in this space. They are also the kind of result that a fully independent replication would strengthen considerably.

Cannabichromene is the clearest example of the problem this page is about. It appears in product descriptions with anti-inflammatory and neuroprotective claims attached, and there is no published study in which CBC alone was administered to human participants and outcomes were measured.

What exists is preclinical. A 2024 study in Toxicology by Gao and colleagues at the US Food and Drug Administration compared hemp extract and four constituent cannabinoids in hepatocytes derived from human induced pluripotent stem cells, and ranked transcriptional potency as CBN, then CBD, then CBC, then CBG, consistent with the order of their cytotoxicity values. That is a laboratory safety signal, not a therapeutic finding.

The only human data touching CBC comes from a 2026 real-world study in Clinical Therapeutics by Kruger and colleagues, in which one of three tested products contained 3 mg of CBC alongside tetrahydrocannabinolic acid, cannabidiolic acid, and CBG. Participants across chronic pain conditions reported symptom improvement on all three products, which tells you about a four-cannabinoid combination and nothing about CBC.

Anyone describing what CBC does in humans is describing something that has not been measured.

Tetrahydrocannabivarin has more human data behind it than the others, and the data are more interesting. A 2016 randomized, double-blind, placebo-controlled trial in Diabetes Care by Jadoon and colleagues randomized 62 people with non-insulin-treated type 2 diabetes across five arms for 13 weeks, including THCV at 5 mg twice daily. The primary endpoint, change in HDL cholesterol, was not met. Compared with placebo, however, THCV significantly lowered fasting plasma glucose by an estimated 1.2 mmol per litre and improved a modelled measure of pancreatic beta cell function, and it was well tolerated.

A 2015 imaging study in the International Journal of Neuropsychopharmacology by Rzepa, Tudge, and McCabe gave 20 healthy volunteers a single 10 mg oral dose and found altered resting state connectivity involving the amygdala and default mode network, with no subjective drug effects. That is mechanistic support for the obesity and metabolic hypothesis rather than a clinical outcome.

The most practically important human study is a 2023 dose-ranging trial in Cannabis and Cannabinoid Research by Peters and colleagues, which gave single oral doses of 12.5 to 200 mg to healthy adults. Most adverse events were mild and euphoric mood was the most common one. At 100 and 200 mg, participants reported feeling and liking a drug effect. And 78 of 79 urine drug screens taken eight hours after an active dose tested positive for THC. THCV is not the non-intoxicating compound its marketing implies at higher doses, and it will show up on a drug test.

Rank the compounds honestly and the picture is clear. CBD has regulatory-grade trial evidence in specific epilepsy syndromes and clean negative results elsewhere. THC has moderate-quality evidence for pain and spasticity from dozens of trials. THCV has one 13-week randomized metabolic trial that missed its primary endpoint while moving glycemic secondary endpoints, plus dose-ranging safety data. CBN has two randomized sleep trials, both industry connected, one of which missed its primary endpoint. CBG has one small positive crossover trial and one small dose-escalation study that found little. CBC has nothing in humans.

Sample sizes are the other axis. The CBG trial enrolled 34 people. The THCV metabolic trial enrolled 62 across five arms, meaning roughly a dozen per arm. These are pilot-scale studies generating hypotheses, and they should be cited as such rather than as demonstrations of efficacy.

Sponsorship is concentrated in exactly the compounds with the most commercial momentum. Both CBN sleep trials had industry involvement, and the CBG anxiety trial was conducted as a remote field trial over video rather than in a laboratory, which limits control over conditions and product handling.

Product identity is a second problem. Trials use characterized isolates or defined formulations. Consumer products carrying the same three letters vary in actual content, and independent testing of the retail CBD market has repeatedly found label inaccuracy. A trial result for 20 mg of verified CBG does not transfer to a gummy claiming 20 mg of CBG.

Single-dose acute studies also cannot speak to sustained use. Both CBG studies measured acute effects over hours. Neither tells you what daily CBG does over weeks, and the 2026 authors said so directly, calling for chronic dosing studies.

None of this shows that minor cannabinoids are ineffective. Absence of trials is not evidence of absence of effect, and several of these compounds have plausible pharmacology that nobody has yet tested properly in people.

It also does not show that any of them treat a disease. Not one trial cited here used a disease-modification endpoint. Anxiety ratings, sleep disturbance scores, fasting glucose, and connectivity measures are all short-horizon outcomes.

And it does not establish safety in populations that matter clinically. Every human study cited enrolled healthy adults or a narrow patient group over days to weeks. There is no long-term safety data for any minor cannabinoid, and no data in pregnancy, in children, or in people on complex medication regimens.

The pattern here repeats a familiar cycle in supplement markets: a compound with an appealing mechanistic story reaches shelves years before the first controlled trial, and the trial, when it arrives, is smaller and more equivocal than the marketing. What is different in cannabis is that the trials are now arriving quickly, which gives the field a real chance to correct its own claims.

It is worth noticing which direction the corrections have gone. The CBN sleep trials found narrower effects than the marketing claims. The CBG dose study found less than the first CBG trial did. The THCV trial missed its lipid endpoint. None of these results is a disaster, and all of them are smaller than the promise.

Meanwhile the entourage concept, which is invoked constantly to justify multi-cannabinoid products, has essentially no controlled human evidence behind it in this literature. The clearest test available found that adding CBD at three different doses did not improve on CBN alone for sleep.

I get asked about these compounds weekly, and my honest position is that I find several of them interesting and none of them established. CBG is the one I watch most closely, because the anxiety signal in the Washington State trial is the kind of result I would want to see replicated in a proper laboratory setting with a patient population rather than healthy volunteers.

CBN is where I have to manage expectations most often. Patients arrive convinced it is a sedative. The better of the two trials found that it reduced nighttime awakenings and overall sleep disturbance and did not significantly change sleep quality, sleep onset, or daytime fatigue. That is a narrow effect, and it is not a substitute for working out why someone is not sleeping.

The THCV drug screen finding is the one I make sure people hear. If you drive commercially, hold a safety-sensitive job, or are on probation, a product sold as non-intoxicating that produces a positive THC urine screen at eight hours is a serious problem, and most people selling it are not telling you that.

Treat minor cannabinoids as early-stage, not as established options. CBD and THC have real trial evidence with known limits. THCV, CBN, and CBG each have one to three small human studies with mixed results, several industry connected. CBC has no published human data at all. If you try one, define the target, give it a defined trial period, measure it, and tell your clinicians what you are taking.

When you read a claim about a cannabinoid, ask one question: was this measured in people? Cell culture, mouse models, and receptor binding studies generate hypotheses and produce the confident verbs that fill product pages. A human trial produces a number, a confidence interval, and a list of what did not change. Only the second kind of source can tell you what to expect.